IMMPACT

Project ID: 672454
Funded under: H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument 
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being

Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer.

From 2015-06-01 to 2018-05-31, closed project | IMMPACT Website

Project details

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>EUR 4 244 969,25</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU contribution:</td>
<td>EUR 4 244 969</td>
</tr>
<tr>
<td>Coordinated in:</td>
<td>Sweden</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic(s):</th>
<th>PHC-12-2014 - Clinical research for the validation of biomarkers and/or diagnostic medical devices</th>
</tr>
</thead>
<tbody>
<tr>
<td>Call for proposal:</td>
<td>H2020-SMEINST-2-2014 See other projects for this call</td>
</tr>
<tr>
<td>Funding scheme:</td>
<td>SME-2 - SME instrument phase 2</td>
</tr>
</tbody>
</table>

Objective

The IMMPACT project aims to perform the clinical validation of a serum biomarker signature for the early diagnosis of pancreatic cancer. The biomarker signature is based on the world’s most advanced recombinant antibody microarray platform owned by Immunovia AB. The underlying technology is affinity proteomics. The biomarker signature hence exploits the body’s own detection network for the diagnosis of cancer. The initial retrospective clinical studies have confirmed that the biomarker signature can accurately separate pancreatic cancer patients from healthy individuals. The implication is that the signature, once validated by a robust method, has a very high potential for the short-term uptake into clinical practice. The European dimension of the project lies in the validation of the biomarker signature that will make it possible for the first time to accurately diagnose pancreatic cancer in an asymptomatic stage (I and II) when the cancer is resectable. The results of the project will help to build up evidence that pancreatic cancer can be detected at an early stage, thus laying the basis for the future implementation of screening programmes of population groups at risk. The project stems from the unmet clinical need for the early detection of PDAC. Pancreatologists need a reliable biomarker for the early diagnosis (yes/no) diagnosis of pancreatic cancer. The test should primarily indicate whether the patient has cancer, not if the patient has a high risk of getting cancer. The new biomarker signature will address those needs and allow Immunovia to benefit from the tremendous business opportunity. Immunovia’s business strategy is based on extensive efforts towards validating the new biomarker signature by retrospective and prospective clinical trials. The validation to be undertaken in the project will accelerate an international clinical uptake of Immunovia’s blood based-tests. The project is thus fully aligned with Immunovia’s business development strategy.

Related information

**Result In Brief**
New early detection technology could lead to increased survival from pancreatic cancer

**Report Summaries**
Periodic Reporting for period 3 - IMMPACT (Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer.)
Coordinator
IMMUNOVIA AB
SCHEELEVAGEN 2 MEDICON VILLAGE
223 81 LUND
Sweden

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution: EUR 4 244 969

Last updated on 2017-08-04
Retrieved on 2019-05-18

© European Union, 2019